Article

Daily Medication Pearl: Aggrenox (Aspirin/ER, Dipyridamole)

Aggrenox is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.

Medication Pearl of the Day: Aggrenox (Aspirin/ER, Dipyridamole)

Indication: Aggrenox is a combination antiplatelet agent indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.

Aggrenox reduces the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.

Aggrenox

Insight:

  • Dosing: One capsule twice daily (morning and evening) with or without food.
  • Dosage forms: Capsule 25 mg aspirin/200 mg extended-release dipyridamole.
  • Adverse events (AEs): The most frequently reported AEs (>10% and greater than placebo) were headache, dyspepsia, abdominal pain, nausea, and diarrhea.
  • Mechanism of action: The antithrombotic action of Aggrenox is the result of the additive antiplatelet effects of dipyridamole and aspirin.
  • Manufacturer: Boehringer Ingelheim

Sources:

Related Videos
Heart with stethoscope | Image Credit: © DARIKA - stock.adobe.com
Senior Doctor is examining An Asian patient.
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Healthcare, pharmacist and woman at counter with medicine or prescription drugs sales at drug store.
Image Credit: © Birdland - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix